The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Pathological growth of cardiomyocytes (hypertrophy) is a major determinant for the development of heart failure, one of the leading medical causes of mortality worldwide. Here we show that the microRNA (miRNA)-212/132 family regulates cardiac hypertrophy and autophagy in cardiomyocytes. Hypertrophic stimuli upregulate cardiomyocyte expression of miR-212 and miR-132, which are both necessary and sufficient to drive the hypertrophic growth of cardiomyocytes. MiR-212/132 null mice are protected from pressure-overload-induced heart failure, whereas cardiomyocyte-specific overexpression of the miR-212/132 family leads to pathological cardiac hypertrophy, heart failure and death in mice. Both miR-212 and miR-132 directly target the anti-hypertrophic and pro-autophagic FoxO3 transcription factor and overexpression of these miRNAs leads to hyperactivation of pro-hypertrophic calcineurin/NFAT signalling and an impaired autophagic response upon starvation. Pharmacological inhibition of miR-132 by antagomir injection rescues cardiac hypertrophy and heart failure in mice, offering a possible therapeutic approach for cardiac failure. Heart failure is often a consequence of pathological growth of cardiomyocytes or cardiac hypertrophy. Here Ucar and colleagues report that the microRNAs miR-132 and miR-212 promote cardiac hypertrophy and inhibit autophagy in cardiomyocytes by downregulating the transcription factor FoxO3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, fine-tuning of FOXO3 levels has been achieved via a miRNA-132 antagonistic approach,157 that is currently clinically tested (NCT04045405).”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [157]
In the citing paper
“| Cardiomyopathies | Cardiomyocyte‐specific overexpression of miR‐212/132 | Pathological cardiac hypertrophy, heart failure, and premature death, after impaired autophagic response upon starvation | Ucar et al (2012) |”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al (2012)
In the citing paper
“Along similar lines, the cardiomyocyte‐specific overexpression of miRNAs invalidating the transcriptional activity of FOXO3 (Ucar et al, 2012) or activating MTORC1 (Li et al, 2017) precipitates cardiac function, leading to heart failure.”
From Autophagy in major human diseases (2021) · cites this paper as Ucar et al, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Self-citationHomeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Control of translation and mRNA degradation by miRNAs and siRNAs: Table 1.
Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., & Parker, R. (2006) · Genes & Development · doi:10.1101/gad.1399806 · Cited by 2,060
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., Newman, J., Bronson, R. T., Crowley, D., Stone, J. R., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.019 · Cited by 1,590
Cited by
Items 501–600 of 609
Unveiling the Complexities: Exploring Mechanisms of Anthracyclineinduced Cardiotoxicity
Tayal, R., Mannan, A., Singh, S., Dhiman, S., & Singh, T. G. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x322928241021100631 · Cited by 5
“FOXO3 has been demonstrated to suppress or reverse myocardial hypertrophy in numerous preclinical studies [116, 117].”
GLA deficiency causes cardiac hypertrophy via enhanced autophagy
Ou, W., Li, X., Tang, K., Ding, L., Sun, T., Li, Q., & Li, T. (2025) · Science China Life Sciences · doi:10.1007/s11427-023-2731-0 · Cited by 3
“Upregulated autophagy has also been observed in other hypertrophic models, including transverse aorta constriction (TAC) and angiotensin II (Delbridge et al., 2017; Ucar et al., 2012; Xie et al., 2019).”
Circulating MicroRNA-30e Predicts Left Ventricular Hypertrophy In Essential Hypertensive Patients
Xu, H., Xu, Y., Yang, J., & Huang, J. (2020) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.20000447 · Cited by 3
SLC26A4-AS1 Agrava a Hipertrofia Cardíaca Induzida por AngII Aumentando a Expressão de SLC26A4
Han, X., Li, C., Ji, Q., Zhang, L., Xie, X., Shang, H., & Ye, H. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210933 · Cited by 3
Myocardial fibrosis in right heart dysfunction
Agoşton-Coldea, L., & Negru, A. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.005 · Cited by 4
Sahoo, M., Behera, J. K., Behera, B., Jena, B., Behera, B. L., & Bhattacharya, M. (2024) · The Microbe · doi:10.1016/j.microb.2024.100098 · Cited by 3
Han, Y.-C., Wang, L., Zhang, Y., Zhou, A.-J., Wang, Z., Dong, W.-H., Wang, J., Wang, T., & Zou, J. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128311226240730080713 · Cited by 3
The journey of noncoding RNA from bench to clinic
Chhabra, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821972-0.00016-2 · Cited by 3
Белок клото и сердечно-сосудистая система
Тюренков, И. Н., Perfilova, V. N., Нестерова, А. А., & Глинка, Е. Ю. (2021) · Biochemistry (Moscow) · doi:10.31857/s0320972521020020 · Cited by 3
Bencun, M., Britto‐Borges, T., Eschenbach, J., & Dieterich, C. (2022) · Biomedicines · doi:10.3390/biomedicines10020391 · Cited by 3
“The miR-212/132 family is an important regulator of cardiac hypertrophy and heart failure development in experimental model systems as well as in vivo [13].”
BackgroundInfluentialEmerging Roles of Micrornas in Diabetic Cardiomyopathy
Fomison‐Nurse, I. C. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000394 · Cited by 2
“This could be a potential method to be investigated as a therapeutic intervention to prevent development of hypertrophy and heart failure in diabetic cardiomyopathy [43].”
BackgroundMethodInfluentialGene Therapy and Cardiovascular Diseases
Lu, D., Cushman, S., Thum, T., & Bär, C. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_16 · Cited by 4
Self-citationWu, Y., Song, M., Chen, W., Liang, F., Xu, K., Lin, L., & Wu, M. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001729 · Cited by 2
Vatic, M., Derda, A. A., Garfias‐Veitl, T., Sato, R., Lončar, G., Fibbi, G., Doehner, W., Bär, C., Landi, F., Calvani, R., et al. (2025) · Aging Cell · doi:10.1111/acel.70284 · Cited by 2
“Indeed, miR-132 is upregulated in HF and contributes to cardiomyocyte hypertrophy and is involved in pathological cardiac remodelling (Ucar et al. 2012).”
Self-citationIqbal, A., Ghani, M. W., Shao, N., Zhang, Y., Wang, Z., & Pei, R. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05476-9 · Cited by 2
Nanotechnology-driven heart targeting to fulfil the potential of cardiac microRNA therapies
Bellido, N. H., Hernández‐Ainsa, S., Köhler, R., & Ordovás, L. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126643 · Cited by 2
Ehsani, S., Mard‐Soltani, M., Ahmadpour, F., & Shahsavari, G. (2023) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-023-00464-4 · Cited by 3
“MiR-132 is a highly conserved miRNA located on human chromosome 17 that is produced during intergenic transcription and increased in cardiac tissue in response to cardiomyocyte stress [24, 25].”
BackgroundInhibition of miR-146b-5p alleviates isoprenaline-induced cardiac hypertrophy via regulating DFCP1
Liu, S., Su, L., Li, J., Zhang, Y., Hu, X., Wang, P., Liu, P., & Ye, J. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112252 · Cited by 2
Circulating MicroRNAs as Biomarkers in Coronary Heart Disease and Heart Failure
Cameron, V. A., & Pilbrow, A. P. (2014) · microRNA Diagnostics and Therapeutics · doi:10.2478/micrnat-2014-0002 · Cited by 2
Gu, J., Liu, C., & Huo, Z. (2019) · Science Insights · doi:10.15354/si.19.re056 · Cited by 2
“MiR-212 and 132 directly target the anti-hypertrophic gene, leading to overexpression of FoxO3 through hyperactivation of calcineurin/NFAT signaling, which leads to cardiac hypertrophy (54).”
BackgroundHayat, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801032-7.00001-0 · Cited by 4
Hayat, M. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805420-8.00001-9 · Cited by 4
Hayat, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801033-4.00001-1 · Cited by 2
MiR-377 accelerates cardiac hypertrophy by inhibiting autophagy via targeting PPARγ
Shao, J., Lin, W., Lin, B., Wang, Q., Chen, Y., & Fan, C. (2020) · All Life · doi:10.1080/26895293.2020.1808083 · Cited by 2
Cardiovascular disorders and epigenetics
Khalil, C. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00030-x · Cited by 2
Les microARNs : en quoi intéressent-ils les cardiologues ?
Mericskay, M. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.05.005 · Cited by 2
“Les miR-199b, miR-132 et miR-212, augmentés dans le cœur insuffisant chez l’homme et la souris, répriment des voies de signalisation anti-hypertrophique et pro-autophagique [6,7].”
Hayat, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405528-5.00001-8 · Cited by 2
Coats, A. J. S. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1584 · Cited by 1
Hastalıkların Tedavisinde Umut Vadeden Yeni Hedef: FOXO Transkripsiyon Faktörleri
VURANOK, N. (2022) · Hippocrates Medical Journal · doi:10.29228/hmj.11 · Cited by 1
Han, X., Liu, K., Gao, F., Yang, M., & Wang, F. (2023) · Open Medicine · doi:10.1515/med-2023-0754 · Cited by 1
“For instance, it is reported that the knockdown of miR-132 improves heart failure and cardiac hypertrophy in mice [19].”
BackgroundSun, K., & Sun, Y. (2025) · Next research. · doi:10.1016/j.nexres.2025.100484 · Cited by 1
Anticoagulation Therapies and microRNAs in Heart Failure
Spartano, L., Lombardi, M., & Foglieni, C. (2025) · Biomolecules · doi:10.3390/biom15101411 · Cited by 2
“Conversely, the miR-132 drives in vivo the pathological growth of cardiomyocytes in a murine model of left ventricular pressure overload [155], and was suggested as a therapeutic target in HF and cardiac diseases [156,157].”
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 4
Thum, T. (2014) · Cited by 1
Self-citationYujie, X., Dengfeng, G., Zhongwei, L., & Xiaolin, N. (2014) · Chinese Medical Journal · doi:10.1097/00029330-201409200-00024 · Cited by 2
Keeping the Heart Fitm2 during Chemotherapy
Eding, J., & van Rooij, E. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.002 · Cited by 1
“In addition, the fact that long-term overexpression of the miR-132/212 cluster under baseline conditions previously was shown to result in heart failure could underscore a level of caution regarding a long-term increase in the miRs.(14) From a therapeutic perspective, some hurdles must be overcome before increasing le…”
BackgroundThe Janus Face of miR-148a in Cardiac Remodeling and Heart Failure
Hobuß, L., & Thum, T. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.004 · Cited by 1
Self-citationEpigenetic regulation of clinical manifestations of Friedreich's disease
Nuzhny, E. P., Abramycheva, N. Y., Nikolaeva, N. S., Ершова, М. В., Klyushnikov, S. A., Illarioshkin, S. N., & Fedotova, E. Y. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202012001120 · Cited by 1
Hayat, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405529-2.00001-9 · Cited by 1
Hayat, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-405877-4.00001-9 · Cited by 1
MicroRNAs in cardiovascular diseases
Oroujalian, A., & Peymani, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89774-7.00030-3 · Cited by 1
Yang, P., Hao, J. C., Li, M., Zhao, N., & Wu, L. (2023) · Trends in Medical Research · doi:10.3923/tmr.2023.92.101 · Cited by 1
Sun, W., Zhang, P., Zhang, W., Xu, J., Huang, Y., & Li, L. (2024) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-023-00602-x · Cited by 1
“MiR-212/132 can regulate cardiac hypertrophy and cardio-myocyte autophagy [4]. hsa-miR-93-5p is associated with Sporadic Creutzfeldt–Jakob disease [5].”
Advances in pharmacotherapy for heart failure and reduced ejection fraction: what’s new in 2024?
Ismail, Z., Aboughdir, M., Duric, B., Kaka, S., Chan, J. S. K., Bayatpoor, Y., & Harky, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408376 · Cited by 3
“Recent studies have proposed that miRNA-based therapeutics can be designed to improve clinical outcomes for HF patients [123– 125].”
MicroRNAs and Cardiovascular Diseases
Henderson, J. M., Farina, F. M., & Santovito, D. (2024) · Epigenetics and human health · doi:10.1007/978-3-031-64788-8_9 · Cited by 1
Regulation of Autophagy by microRNAs
Tekirdağ, K. A., Öztürk, D. G., & Gözüaçık, D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801032-7.00004-6 · Cited by 1
Noncoding RNAs in Ischemic Cardiovascular Disease and Repair Mechanisms
Landmesser, U., & Jakob, P. (2017) · Cardiac and vascular biology · doi:10.1007/978-3-319-52945-5_4 · Cited by 1
Cao, F., & Ma, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805253-2.00008-0 · Cited by 1
Inter- and Intracellular Mechanisms of Cardiac Remodeling, Hypertrophy and Dysfunction
Heineke, J., Kempf, T., & Bauersachs, J. K. (2019) · Cardiovascular medicine · doi:10.1007/978-3-319-98184-0_2 · Cited by 1
Self-citationHayat, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805421-5.00001-x · Cited by 1
Pelozin, B. R. D. A., Rodrigues, L. F., de Oliveira, E. M., & Fernandes, T. M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100625 · Cited by 1
MicroRNAs in Cardiovascular Disease: From Pathogenesis to Treatment
Barb, I., Vogel, B., Katus, H. A., & Meder, B. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_13 · Cited by 1
“Remarkably, antagomir-132 injection prevented the development of cardiac hypertrophy in mice subjected to pressure overload, hinting at a possible therapeutic relevance of these fi ndings [ 46 ].”
BackgroundPlasma MicroRNA Clusters in Human Left Ventricular Remodeling: A Biomarker and Discovery Platform
Padmanabhan, A., & Haldar, S. M. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004793 · Cited by 1
MicroRNA-Mediated Regulation of Cardiovascular Differentiation and Therapeutic Implications
Foinquinos, A., Viereck, J., & Thum, T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405544-5.00041-1
Self-citationRNAi2015 - Ten years of RNAi Oxford.
Bewicke‐Copley, F., Samuel, P., & Carter, D. R. F. (2015) · PubMed Central · Cited by 2
Cardiovascular Disorders and Epigenetics
Khalil, C. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00014-4 · Cited by 1
Autophagy Networks in Cardiovascular Diseases
García, L., Bustamante, M., Pizarro, M., Quiroga, C., Rodriguez, A. E., Westermeier, F., Bernal-Sore, I., Castro, P., Lavandero, S., & Troncoso, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-30079-5_14
The New Massive Data: miRnomics and Its Application to Therapeutics
Khan, M. A., Mahfooz, M., Sami, G. A., Alsalmi, H. M. A., Mathkoor, A. E. A., Damanhauri, G. A., Rasool, M., & Jamal, M. S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2809-7_8
OBSOLETE: Cardiac Hypertrophy: Signaling and Cellular Crosstalk
Tîrziu, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99834-9
Uso de micro RNA en el manejo de la insuficiencia cardiaca
Arias-Sosa, L. A. (2017) · Archivos de cardiología de México · doi:10.1016/j.acmx.2017.02.003
Wang, X., Gillette, T. G., & Wang, Z. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805253-2.00024-9
Mechanistic Effects of Exercise Training in Preventing or Attenuating Atherosclerosis
Giallauria, F., Giuseppe, R., Morisco, C., Antonio, C., Leosco, D., Ferrara, N., & Vigorito, C. (2015) · Journal of Clinical Exercise Physiology · doi:10.31189/2165-6193-4.1.3
The Role of Bicarbonate Transporters in the Development of Cardiovascular Diseases
Sowah, D. (2014) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3mk65g1d
Feedback Mechanisms for Cardiac-Specific MicroRNAs and cAMP Signaling in Electrical Remodeling
Zhang, X., & Chiamvimonvat, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-44733-1.00024-9
Senger, N. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2020.tde-16122019-113907
Pesce, M., Bär, C., Madonna, R., & Thum, T. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa218
Self-citationEpigenetic Regulation of the Clinical Signs of Friedreich’s Disease
Nuzhny, E. P., Abramycheva, N. Y., Nikolaeva, N. S., Ершова, М. В., Klyushnikov, S. A., Illarioshkin, S. N., & Fedotova, E. Y. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-00998-9
Myocardial BDNF regulates cardiac bioenergetics through the transcription factor Yin Yang 1Preprint
Yang, X., Zhang, M., Xie, B., Zimmerman, R., Wang, Q., Wei, A., Peng, Z., Khalifa, M., Reynolds, M. J., Om, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.19.427213
“Enhanced MeCP2 and miR-212/132 signaling have been reported to play an important role in cardiac hypertrophy (37, 38).”
BackgroundTherapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease
Winkler, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822258-4.00010-9 · Cited by 1
Regulatory RNAs in cardiovascular disease
Madè, A., Greco, S., & Martelli, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822258-4.00019-5
Tang, C., Su, Q., Zhao, H., Sui, H., Liang, J., Zhu, L., Si-yun, Y., & Liu, T. (2021) · Archives of Medical Science · doi:10.5114/aoms/130649 · Cited by 1
“Distinct miRs that play a vital role in cardiomyocyte hypertrophy include miR-208, -133, and -212/132 [9-11], whereas miR-21, -30, -133, and, -29 have been confirmed to be involved in fibrosis [12-16].”
Zhang, F., Gao, F., Wang, K., Liu, X., & Zhang, Z. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02606-0
Concepts and Design of Introducing Synthetic MicroRNAs into Mammalian Cells
Hydbring, P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2071-7_11
The Epigenetics and Molecular Interplay in Obesity and Associated Complications
Soni, H., & Dangwal, S. (2021) · Advances in biochemistry in health and disease · doi:10.1007/978-3-030-84763-0_4
Self-citationLeonardy, J., & Bär, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.822280
Hayat, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-405530-8.00001-7
Russell, A. P. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726178103.793549731
Cardiac Hypertrophy: Signaling and Cellular Crosstalk
Tîrziu, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99834-x · Cited by 1
Kovács, M. G. (2022) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11174
Atrial myocytes-derived exosomal microRNA contributes to atrial fibrosis in atrial fibrillationPreprint
Hao, H., Yan, S. R., Zhao, X., Han, X., Fang, N., Zhang, Y., Dai, C., Li, W., Yu, H. M., Gao, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1621646/v1
Kardiale Effekte der m6A-Methylierung auf micro-RNA-Bindung
von Limont, N. L. W. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9441
microRNAs as critical regulators in heart development and diseases
Rani, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91305-8.00005-3
Moreyra, C., Moreyra, E. A., & Rozich, J. D. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000494
Therapeutic Innovations for Heart Failure
Remes, A. K., Frank, D., & Müller, O. J. (2023) · Cardiac and vascular biology · doi:10.1007/978-3-031-23965-6_13
The Role of Heat Shock Protein A4 (HSPA4) in the Heart
Rodrigues, D. M. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9959 · Cited by 1
Márványkövi, F. M. (2023) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.11611
New and emerging therapies in heart failure
Rosano, G. M. C., Filippatos, G. S., & Starling, R. C. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780198891628.003.0052
Epigenetic Therapeutics in Human Heart Failure
Leon, S., Liu, C., & Tang, W. H. W. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.08.003
Cardiac Hypertrophy: Signaling and Cellular Crosstalk
Ohadi, L., Donempudi, V. K., & Tîrziu, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00070-4
Role of myocardium-derived exosomal miRNAs in doxorubicin-induced cardiomyopathy
Li, C., Song, Y., Cao, B., Li, J., Xu, F., Du, W., Zhang, Z., Su, B., Chen, X., Yu, Q., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149842
Hao, H., Yan, S. R., Zhao, X., Han, X., Fang, N., Zhang, Y., Dai, C., Li, W., Yu, H., Gao, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20968206
Ehsani, S., Mard‐Soltani, M., Ahmadpour, F., & Shahsavari, G. (2023) · Figshare · doi:10.6084/m9.figshare.24847123
Pizzol, M. S. D., Ibelli, A. M. G., Cantão, M. E., Campos, F. G., de Oliveira, H. C., de Oliveira Peixoto, J., Fernandes, L. T., de Castro Tavernari, F., Morés, M. A. Z., Bastos, A. P. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26671932
Hao, H., Yan, S. R., Zhao, X., Han, X., Fang, N., Zhang, Y., Dai, C., Li, W., Yu, H., Gao, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20968209
Papannarao, J. B., Coffey, S., Gray, A., Williams, M. J. A., & Katare, R. (2025) · Bioscience Reports · doi:10.1042/bsr20253835
Past, Present and Future of Regenerative Gene Therapy for Ischemic Heart Failure
González, L. F., Bouwman, M., & Bakkers, J. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10731-x
Ribas, L. M., Muner, K., Elshafie, N. O., Rozanski, E. A., Conrado, F. O., Santos, L. D., & dos Santos, A. P. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1755166
“In a mouse cardiomyocyte model, Ucar et al. (61) reported that miR-212/132 downregulates FoxO3, modulating autophagy and promoting hypertrophy.”
MicroARNs, marqueurs de la pathologie valvulaire aortique
Nader, J. (2019) · theses.fr (ABES) · doi:10.70675/4d490f42z8b44z4281zb256zd9d9d5976dab
The aging modulator miR-29 is essential for adult cardiomyocyte functionPreprint
Roiz‐Valle, D., Folgueira, C., Moledo-Nodar, L., Tartiere, A. G., Cicuéndez, B., Romero-Becerra, R., Rodríguez, F., He, Y.-W., Freije, J. M. P., Sabio, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.24.718944
Extracellular vesicles from hypertrophic cardiomyocytes promote breast cancer progression
Chen, W., Yao, Y., Xin, B., An, P., Dai, Y., Gao, H., Yang, J., Wang, X., Shi, Y., Zhu, Z., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10104-3
“Forinstance,plasmamiR-1,miR-212/132, andmiR-133arestronglyimplicatedintheregulationofmyocardial hypertrophy 30 – 32 .”
Metadata
- Authors
- Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., Remke, J., Caprio, M., Jentzsch, C., Engelhardt, S., Geisendorf, S., Glas, C., Hofmann, T. G., Nessling, M., Richter, K., Schiffer, M., Carrier, L., Napp, L. C., Bauersachs, J., Chowdhury, K., & Thum, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- IRCCS San Raffaele Roma (IT)
- Technical University of Munich (DE)
- Max Planck Institute for Biophysical Chemistry (DE)
- German Cancer Research Center (DE)
- Mount Desert Island Biological Laboratory (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Chowdhury, Kamal
- Thum, Thomas
- ORCID
- Venue
- Nature Communications
- Published
- 2012-09-25
- Volume
- 3
- Issue
- 1
- Pages
- 1078-1078
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3657998
- OpenAlex
- W2101080348
- Cited by
- 610
- References
- 46
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 47 · 2023: 32 · 2022: 60 · 2021: 53 · 2020: 52 · 2019: 41 · 2018: 43 · 2017: 51 · 2016: 47 · 2015: 67 · 2014: 44 · 2013: 26
- FWCI
- 28.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Baden-Württemberg Stiftung
- Deutsches Krebsforschungszentrum
- Deutsche Forschungsgemeinschaft (DFG-TH903/10-1, 01EO0802, SCHI587/3)
- Bundesministerium für Bildung und Forschung (01EO0802)
- Max-Planck-Gesellschaft
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- miR-212, miR-132, cardiac hypertrophy, cardiomyocyte autophagy, heart failure, FOXO3, pressure overload, antagomir, cardiomyocyte-specific overexpression, starvation-induced autophagy
- MeSH terms
- Antagomirs, Animals, Autophagy, Cells, Cultured, Cardiomegaly, Male, Mice, Transgenic, Oligonucleotides, Calcineurin, Reverse Transcriptase Polymerase Chain Reaction, Myocytes, Cardiac, MicroRNAs, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.